RxDoctor Payments DataLook up a doctor →

Maria Younes, MD

Neurology with Special Qualifications in Child Neurology · Cumberland, RINPI 1205840659

Payments from drug & device makers

$12,978in general payments, 2019–2025

Across 689 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$2K
  • UCB, Inc.$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • Tris Pharma Inc$1K
  • Ironshore Pharmaceuticals Inc.$1K
  • Corium, LLC$911
  • plus $6K from 31 others

What the payments were for

  • Food & beverage$12,963100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurology with special qualifications in child neurology providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,982
Medicare patients
19
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeppraLevetiracetam15$39,079
Depakote ErDivalproex Sodium36$21,817
Topiramate ErTopiramate11$21,387
LamictalLamotrigine25$18,869
Keppra XrLevetiracetam11$16,603
FycompaPerampanel13$13,873
EpidiolexCannabidiol (Cbd)13$11,898
RisperdalRisperidone25$11,726
Depakote SprinkleDivalproex Sodium28$11,615
LyricaPregabalin13$10,983
ValtocoDiazepam16$10,791
Lamotrigine ErLamotrigine34$6,888
Divalproex Sodium ErDivalproex Sodium49$3,542
Risperidone OdtRisperidone26$3,497
Desmopressin Acetate24$2,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$607$13,87313 claims
Neurelis, Inc.Valtoco$1,579$10,79116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other neurology with special qualifications in child neurology in Cumberland

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →